Harvard Bioscience Q3 Earnings Announcement
Harvard Bioscience, Inc. (NASDAQ: HBIO), a prominent player in the life sciences sector, is set to disclose its financial results for the third quarter of 2024 on November 7, 2024, before the market opens. This announcement is highly anticipated as it highlights the company's progress and performance in a continually evolving industry.
Details of the Earnings Conference Call
Following the release of the earnings report, Harvard Bioscience will host a conference call at 8:00 a.m. Eastern Time on the same day. This interactive session allows shareholders and interested parties to gain insights directly from the company's leadership regarding the financial results and future outlook. Participants eager to ask questions during the call must complete the registration process.
How to Register for the Conference Call
To join the call, interested individuals should complete their registration through the company's website. Once registered, they will receive essential dial-in numbers and a unique PIN to access the call. This process ensures that participants can engage meaningfully during the discussion.
Audio Webcast for Broader Participation
For those who prefer to listen to the audio-only version, an option is available on the investor relations section of the Harvard Bioscience website. This web-based format allows for broader participation, accommodating those who may not be able to ask questions directly but wish to stay informed about the company's performance.
Accessing Financial Information
During the call, financial information, including the earnings release and a detailed slide presentation, will be accessible on the Investor Relations section of the Harvard Bioscience website. This transparency is crucial for investors looking to analyze the company's financial health rigorously.
About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. stands at the forefront of innovation in designing, manufacturing, and selling cutting-edge technologies that facilitate significant advancements in life science research. Their portfolio encompasses products and services tailored for various applications, including pharmaceutical research, therapy discovery, biomanufacturing, and preclinical testing. The company's extensive customer base includes prestigious academic institutions, government laboratories, and leading pharmaceutical and biotechnology organizations, positioning Harvard Bioscience as a cornerstone in the life sciences community.
Global Reach and Operations
With operations spanning across the United States, Europe, and China, Harvard Bioscience leverages a combination of direct sales and distribution channels to reach customers worldwide. This global presence enhances their ability to respond to the diverse needs of their clients, making them a reliable partner in the life science arena.
Company Contact Information
If you have questions or need further information about the upcoming conference call or general inquiries, you can reach out directly to:
Jennifer Cote
Chief Financial Officer
(508) 893-3120
Investors Contact Information
Investors can contact:
Three Part Advisors
Sandy Martin
Email: HBIO@threepa.com
(214) 616-2207
Frequently Asked Questions
What is the date for Harvard Bioscience's Q3 earnings call?
The conference call is scheduled for November 7, 2024, at 8:00 a.m. Eastern Time.
How can I participate in the earnings conference call?
Participants must register in advance to receive dial-in details and a unique PIN to access the call.
Will there be a presentation during the earnings call?
Yes, there will be a slide presentation accompanying the earnings call, in addition to the financial results being discussed.
Where can I find the financial information discussed during the call?
The financial release and related materials will be made available on the Investor Relations section of Harvard Bioscience’s website.
Who can I contact for more investor-related inquiries?
For investor inquiries, you can contact Sandy Martin at Three Part Advisors or reach out to Jennifer Cote, the CFO of Harvard Bioscience.
